Is Iterum Therapeutics plc (ITRM) a Buy, Sell, or Hold?
Iterum Therapeutics plc
NASDAQ:ITRM
$0.03 USD
$0.0 (-10.98%)
- Volume
- 49.3M
- Average Volume
- 16.33M
- Market Capitalization
- $1.6M
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.42
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.13
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Corey N. Fishman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ITRM |
| CUSIP | G6333L101 |
| CIK | 0001659323 |
| Web | https://www.iterumtx.com |
| Phone | 353 1 669 4820 |
| Currency | USD |
| Employees | 9 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | -4.57 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.13 |
| Quick Ratio | 1.96 |
| Cash Ratio | 1.71 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 4.10 |
| Cash Flow | -0.34 |
| Price / Cash Flow | -0.10 |
| Price / Book | -0.19 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.26 |
| Trailing P/E Ratio | -0.06 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-24.77M |
| Net Margin | -5225.38% |
| Pretax Margin | -5161.03% |
| Return on Equity | 442.32% |
| Return on Assets | -62.70% |
Financials Score
| AltmanZ Score | -23.98 |
| Piotroski Score | 4.00 |
| Working Capital | 7.3M |
| Total Assets | 32.5M |
| Ebit | -24.39M |
| Market Cap | 1.6M |
| Total Liabilities | 39.88M |
Poll Results
About Iterum Therapeutics plc (NASDAQ:ITRM) Stock
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland. ...
Frequently Asked Questions
-
What is the current Iterum Therapeutics plc (ITRM) stock price?
-
Iterum Therapeutics plc(NASDAQ:ITRM) stock price is $0.03 in the last trading session. During the trading session, ITRM stock reached the peak price of $1.42 while $0.0271 was the lowest point it dropped to. The percentage change in ITRM stock occurred in the recent session was --10.98% while the dollar amount for the price change in ITRM stock was -$-0.0.
-
ITRM's industry and sector of operation?
-
The NASDAQ listed ITRM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ITRM?
-
Corey N. Fishman | President, Chief Executive Officer & Director
Judith Matthews | Chief Financial Officer
Steven I. Aronin | Senior Vice President & Head of Clinical Development
Kevin Dalton | Senior Director of Legal Affairs & Company Secretary
Tom Loughman | Senior Vice President of Technical Operations -
How many employees does ITRM have?
-
Number of ITRM employees currently stands at 9. ITRM operates from Fitzwilliam Court, Dublin, None 2, IE.
-
Link for ITRM official website?
-
Official Website of ITRM is: https://www.iterumtx.com
-
How do I contact ITRM?
-
ITRM could be contacted at phone #353 1 669 4820 and can also be accessed through its website. ITRM operates from Fitzwilliam Court, Dublin, None 2, IE.
-
How many shares of ITRM are traded daily?
-
The average number of ITRM shares traded daily for last 3 months was 16.33M.
-
What is the market cap of ITRM currently?
-
The market value of ITRM currently stands at $1.6M with its latest stock price at $0.03